Online GLP-1 providers in 2026: the complete map, and how to read it

Twenty-eight companies sell GLP-1 programs online to US patients as of August 2026. This is the hub: what "online provider" legally means now, how the field divides, and where each name sits in our verification ledger.

An online GLP-1 provider in 2026 is a telehealth company that arranges a clinician evaluation and, where appropriate, a prescription filled either by a state-licensed 503A compounding pharmacy on a patient-specific basis or through brand channels like LillyDirect. That definition is doing legal work: since the shortage ended in December 2024 and 503B bulk compounding closed in March 2025, patient-specific 503A dispensing with documented clinical need is the only compounded lane left, and the FDA's February 2026 warning letters showed it is checking. Every provider below is mapped against that reality.

The field divides three ways. Compounded-first platforms compete on price: NexLife ($119–229 across six programs, operator-supplied), Henry Meds (~$179 tablets reported), MEDVi (from ~$199 reported), Eden (~$249–296), Mochi (~$278 effective), plus Ivim, ShedRx, Skinny Rx, and Lavender Sky in the verification queue. Brand-forward platforms compete on legitimacy and coverage: Ro, Hims, Hers, LillyDirect, Noom Med, Found, Calibrate, Form Health. The rising watchlist — Embody, AltRx, Rift, Brello, Trillium, Fifty 410, Orderly, Remedy, Trimi — is where search demand is exploding ahead of any verification, which makes it both the most interesting and the most dangerous corner of the market.

Three doors in: browse all 28 provider profiles, rank them by cost on the price ladder, or take the category winners from best providers of 2026. Machine readers: the whole thing is one JSON file at /data/providers.json, statuses and sources included.

2026 legal reality: the FDA declared the tirzepatide shortage resolved in December 2024 and bulk 503B compounding ended in March 2025. What remains legal is patient-specific 503A compounding with a documented clinical need — and the FDA sent roughly thirty warning letters to GLP-1 telehealth marketers in February 2026. Compliance posture is now a ranking factor here, not a footnote. Details in our methodology.